NASDAQ:KURAKura Oncology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kura Oncology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.14 +0.19 (+2.39 %) (As of 04/5/2020 04:00 PM ET) Add Compare Share Today's Range$7.69Now: $8.14▼$8.2650-Day Range$6.45MA: $10.47▼$12.6052-Week Range$6.35Now: $8.14▼$21.42Volume460,004 shsAverage Volume472,072 shsMarket Capitalization$369.80 millionP/E RatioN/ADividend YieldN/ABeta2.05 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. The company was founded in 2014 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingKura Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.29, Kura Oncology has a potential upside of 235.2% from its current price of $8.14.Amount of Analyst CoverageKura Oncology has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesKura Oncology has received 326 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKura Oncology has received 296 “underperform” votes. (Add your “underperform” vote.)Community SentimentKura Oncology has received 52.41% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote “Outperform” if you believe KURA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKura Oncology does not currently pay a dividend.Dividend GrowthKura Oncology does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kura Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 11.00% of the stock of Kura Oncology is held by insiders.Percentage Held by Institutions85.59% of the stock of Kura Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kura Oncology are expected to grow by 6.74% in the coming year, from ($1.93) to ($2.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kura Oncology is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kura Oncology is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKura Oncology has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KURA Previous Symbol CUSIPN/A CIK1422143 Webhttp://www.kuraoncology.com/ Phone858-500-8800Debt Debt-to-Equity Ratio0.03 Current Ratio15.40 Quick Ratio15.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.83 per share Price / Book1.69Profitability EPS (Most Recent Fiscal Year)($1.51) Net Income$-63,140,000.00 Net MarginsN/A Return on Equity-29.76% Return on Assets-27.10%Miscellaneous Employees43 Outstanding Shares45,430,000Market Cap$369.80 million Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive KURA News and Ratings via Email Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:KURA Rates by TradingView Kura Oncology (NASDAQ:KURA) Frequently Asked Questions How has Kura Oncology's stock been impacted by COVID-19 (Coronavirus)? Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, KURA shares have decreased by 15.6% and is now trading at $8.14. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Kura Oncology? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kura Oncology. When is Kura Oncology's next earnings date? Kura Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Kura Oncology. How were Kura Oncology's earnings last quarter? Kura Oncology Inc (NASDAQ:KURA) announced its quarterly earnings results on Tuesday, February, 25th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.03. View Kura Oncology's earnings history. What price target have analysts set for KURA? 7 brokers have issued 1 year target prices for Kura Oncology's stock. Their forecasts range from $22.00 to $30.00. On average, they anticipate Kura Oncology's share price to reach $27.29 in the next twelve months. This suggests a possible upside of 235.2% from the stock's current price. View analysts' price targets for Kura Oncology. Has Kura Oncology been receiving favorable news coverage? News articles about KURA stock have been trending very negative on Sunday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Kura Oncology earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutKura Oncology. Who are some of Kura Oncology's key competitors? Some companies that are related to Kura Oncology include Epizyme (EPZM), Theravance Biopharma (TBPH), SAGE Therapeutics (SAGE), Corcept Therapeutics (CORT), Pacira Biosciences (PCRX), Insmed (INSM), Dicerna Pharmaceuticals (DRNA), Constellation Pharmaceuticals (CNST), Innoviva (INVA), Ligand Pharmaceuticals (LGND), Karyopharm Therapeutics (KPTI), ZEALAND PHARMA/S (ZEAL), CytoDyn (CYDY), Tricida (TCDA) and Heron Therapeutics (HRTX). What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Amarin (AMRN), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Exelixis (EXEL), Aduro BioTech (ADRO), ACADIA Pharmaceuticals (ACAD), Sorrento Therapeutics (SRNE) and Viking Therapeutics (VKTX). Who are Kura Oncology's key executives? Kura Oncology's management team includes the following people: Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 50)Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 54)Dr. Marc Grasso, CFO & Chief Bus. OfficerMr. John Farnam, Chief Operating OfficerMr. Pete De Spain, VP of Investor Relations & Corp. Communications What is Kura Oncology's stock symbol? Kura Oncology trades on the NASDAQ under the ticker symbol "KURA." How do I buy shares of Kura Oncology? Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Kura Oncology's stock price today? One share of KURA stock can currently be purchased for approximately $8.14. How big of a company is Kura Oncology? Kura Oncology has a market capitalization of $369.80 million. The company earns $-63,140,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Kura Oncology employs 43 workers across the globe. View additional information about Kura Oncology. What is Kura Oncology's official website? The official website for Kura Oncology is http://www.kuraoncology.com/. How can I contact Kura Oncology? Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected] This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: How the Dogs of the Dow Strategy Works
